Market Overview:
FSGS is a kidney disorder that affects the filtering units of the kidneys, called glomeruli. The cause of FSGS is unknown, but it may be related to an autoimmune response or environmental factors. Symptoms include protein in the urine, high blood pressure (hypertension), and swelling in the hands and feet. Treatment for FSGS depends on its severity and may include drug therapy, dialysis, or a kidney transplant.
 Industry Outlook.svg)
Product Definition:
Focal Segmental Glomerulosclerosis (FSGS) is a kidney disorder that results in scarring of the glomeruli. This can lead to proteinuria, hypertension, and renal failure. FSGS is important because it can lead to end-stage renal disease and requires treatment.
Diagnosis (Kidney Biopsy and Creatine Test):
Diagnosis (Kidney Biopsy and Creatine Test) is a blood test used to identify problems with the kidney or urinary tract. The test involves taking a small sample of blood from the renal vein, which is then sent to a laboratory for analysis. In most cases, this procedure can diagnose focal segmental glomerulosclerosis (FSGS), also known as Granular Cell Arteriovenous Malformation (GCAM).
Treatment (Drug Therapy, Dialysis, and Kidney Transplant):
The global Treatment and it's usage in Focal Segmental Glomerulosclerosis (FSGS) market is classified on the basis of treatment types, end-use, and geography. On the basis of treatment type, the global market is classified into Drug Therapy (ATC), Dialysis, Kidney Transplantation (KTP). ATC held a major share in 2014 owing to its high efficiency rates as compared to other treatments.
Application Insights:
Based on application, the global market is segmented into hospitals, ambulatory surgical centers (ASCs), specialty clinics and other centers. Hospitals held the largest share in 2017 owing to availability of advanced healthcare facilities and a large patient base at a time when FSGS is diagnosed for the first time or when drug therapy cannot remove all nephrotoxicants from blood circulation.
FSGS treatment involves various drugs that are used either alone or in combination to get rid of proteinuria and reduce its progression to chronic kidney disease (CKD). Drug therapies employed for focal segmental glomerulosclerosis include angiotensin-converting enzyme inhibitors (ACEIs), angiotensin II receptor antagonists (ARAs) and/or spironolactone. The use of these drugs along with regular monitoring helps in reducing FSGS related complications as well as death rate among patients suffering from this condition.
Regional Analysis:
North America dominated the global market in 2017. High adoption of FSGS diagnostic and treatment procedures, rising healthcare expenditure, and favorable reimbursement policies are some of the major factors responsible for its largest share. In addition, a high prevalence of FSGS coupled with initiatives undertaken by government organizations to raise awareness about this disease is expected to drive growth during the forecast period.
Asia Pacific is anticipated to be the fastest-growing region over the forecast period owing to increasing healthcare expenditure and growing patient awareness levels regarding available treatment options for focal segmental glomerulosclerosis.
Growth Factors:
- Increasing incidence of FSGS due to various factors such as increase in the number of patients with diabetes and hypertension
- Growing awareness about the disease and its treatment options
- Rising demand for better and more effective therapies for FSGS
- Availability of government funding for research on FSGS
- Entry of new players in the market
Scope Of The Report
Report Attributes
Report Details
Report Title
Focal Segmental Glomerulosclerosis (FSGS) Market Research Report
By Type
Diagnosis (Kidney Biopsy and Creatine Test), Treatment (Drug Therapy, Dialysis, and Kidney Transplant)
By Application
Hospitals, Ambulatory Surgical Centers, Specialty Clinics
By Companies
Variant Pharmaceuticals, ChemoCentryx, Retrophin, Novartis, Pfizer, AstraZeneca, Sanofi, GlaxoSmithKline, Teva Pharmaceutical, Variant Pharmaceuticals
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
154
Number of Tables & Figures
108
Customization Available
Yes, the report can be customized as per your need.
Global Focal Segmental Glomerulosclerosis (FSGS) Market Report Segments:
The global Focal Segmental Glomerulosclerosis (FSGS) market is segmented on the basis of:
Types
Diagnosis (Kidney Biopsy and Creatine Test), Treatment (Drug Therapy, Dialysis, and Kidney Transplant)
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Ambulatory Surgical Centers, Specialty Clinics
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Variant Pharmaceuticals
- ChemoCentryx
- Retrophin
- Novartis
- Pfizer
- AstraZeneca
- Sanofi
- GlaxoSmithKline
- Teva Pharmaceutical
- Variant Pharmaceuticals
 Market Overview.svg)
Highlights of The Focal Segmental Glomerulosclerosis (FSGS) Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Diagnosis (Kidney Biopsy and Creatine Test)
- Treatment (Drug Therapy, Dialysis, and Kidney Transplant)
- By Application:
- Hospitals
- Ambulatory Surgical Centers
- Specialty Clinics
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Focal Segmental Glomerulosclerosis (FSGS) Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
 Market Statistics.svg)
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
FSGS is a type of glomerulosclerosis that affects the small blood vessels in the kidneys. The disease can cause kidney failure over time.
Some of the major companies in the focal segmental glomerulosclerosis (fsgs) market are Variant Pharmaceuticals, ChemoCentryx, Retrophin, Novartis, Pfizer, AstraZeneca, Sanofi, GlaxoSmithKline, Teva Pharmaceutical, Variant Pharmaceuticals.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Focal Segmental Glomerulosclerosis (FSGS) Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Focal Segmental Glomerulosclerosis (FSGS) Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Focal Segmental Glomerulosclerosis (FSGS) Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Focal Segmental Glomerulosclerosis (FSGS) Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Focal Segmental Glomerulosclerosis (FSGS) Market Size & Forecast, 2020-2028
4.5.1 Focal Segmental Glomerulosclerosis (FSGS) Market Size and Y-o-Y Growth
4.5.2 Focal Segmental Glomerulosclerosis (FSGS) Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Diagnosis (Kidney Biopsy and Creatine Test)
5.2.2 Treatment (Drug Therapy
5.2.3 Dialysis
5.2.4 and Kidney Transplant)
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hospitals
6.2.2 Ambulatory Surgical Centers
6.2.3 Specialty Clinics
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Focal Segmental Glomerulosclerosis (FSGS) Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Focal Segmental Glomerulosclerosis (FSGS) Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Diagnosis (Kidney Biopsy and Creatine Test)
9.6.2 Treatment (Drug Therapy
9.6.3 Dialysis
9.6.4 and Kidney Transplant)
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hospitals
9.10.2 Ambulatory Surgical Centers
9.10.3 Specialty Clinics
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Diagnosis (Kidney Biopsy and Creatine Test)
10.6.2 Treatment (Drug Therapy
10.6.3 Dialysis
10.6.4 and Kidney Transplant)
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hospitals
10.10.2 Ambulatory Surgical Centers
10.10.3 Specialty Clinics
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Diagnosis (Kidney Biopsy and Creatine Test)
11.6.2 Treatment (Drug Therapy
11.6.3 Dialysis
11.6.4 and Kidney Transplant)
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hospitals
11.10.2 Ambulatory Surgical Centers
11.10.3 Specialty Clinics
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Diagnosis (Kidney Biopsy and Creatine Test)
12.6.2 Treatment (Drug Therapy
12.6.3 Dialysis
12.6.4 and Kidney Transplant)
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hospitals
12.10.2 Ambulatory Surgical Centers
12.10.3 Specialty Clinics
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Diagnosis (Kidney Biopsy and Creatine Test)
13.6.2 Treatment (Drug Therapy
13.6.3 Dialysis
13.6.4 and Kidney Transplant)
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hospitals
13.10.2 Ambulatory Surgical Centers
13.10.3 Specialty Clinics
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Focal Segmental Glomerulosclerosis (FSGS) Market: Competitive Dashboard
14.2 Global Focal Segmental Glomerulosclerosis (FSGS) Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Variant Pharmaceuticals
14.3.2 ChemoCentryx
14.3.3 Retrophin
14.3.4 Novartis
14.3.5 Pfizer
14.3.6 AstraZeneca
14.3.7 Sanofi
14.3.8 GlaxoSmithKline
14.3.9 Teva Pharmaceutical
14.3.10 Variant Pharmaceuticals
